- Report
- November 2024
- 130 Pages
Asia Pacific
From €1184EUR$1,301USD£1,006GBP
€1692EUR$1,859USD£1,437GBP
- Report
- November 2024
- 150 Pages
Europe
From €1438EUR$1,580USD£1,221GBP
€2054EUR$2,257USD£1,745GBP
- Report
- April 2024
- 350 Pages
Global
From €2447EUR$2,688USD£2,078GBP
€3495EUR$3,840USD£2,969GBP
- Report
- November 2022
- 310 Pages
Global
From €2447EUR$2,688USD£2,078GBP
€3495EUR$3,840USD£2,969GBP
- Book
- January 2015
- 464 Pages
- Book
- October 2012
- 1570 Pages
The Conjugate Vaccine market is a subset of the Vaccines market, which is composed of products designed to prevent and treat infectious diseases. Conjugate Vaccines are a type of vaccine that combines a polysaccharide antigen with a protein carrier, which helps the body to recognize the antigen and mount an immune response. These vaccines are used to protect against a variety of bacterial infections, including meningitis, pneumonia, and sepsis.
Conjugate Vaccines are typically administered to infants and young children, as their immune systems are not yet fully developed and are more susceptible to certain infections. In addition, these vaccines are often used in combination with other vaccines to provide broader protection against multiple diseases.
Notable companies in the Conjugate Vaccine market include GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, and Novartis. Show Less Read more